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The IL12B gene on chromosome 5q31-33 encodes the p40 subunit of interleukin 12, an immunomodulatory
cytokine. To test the hypothesis that the IL12B gene contains polymorphisms associated with asthma, we genotyped
six haplotype-tagging polymorphisms in the IL12B gene, both in 708 children enrolled in the Childhood Asthma
Management Program (CAMP) and in their parents. Using the family-based association test (FBAT) program and
its haplotype (HBAT) and phenotype (PBAT) options, we tested each polymorphism and haplotype for association
with asthma and asthma-related phenotypes. We tested positive associations for replication in a case-control study
comparing 177 adult moderate-to-severe asthmatics with 177 nonasthmatic controls. In whites in the CAMP cohort,
the A allele of the IL12B G4237A polymorphism was undertransmitted to asthmatic children ( , recessivePp .0008
model), the global test for haplotypes for affection status was positive ( , multiallelic x2), and two poly-Pp .009
morphisms were associated with different atopy phenotypes. In addition, we found a strong association between
the IL12B_4237 and IL12B_6402 polymorphisms and an asthma-severity phenotype in whites, which we also
found in the independent population of white adult asthmatics. IL12B may be an important asthma gene.
Chromosome 5q31 contains numerous immunoregula-
tory genes that could inﬂuence asthma and atopy pheno-
types and that has been linked to those phenotypes in
many genetic studies (Meyers et al. 1994; Rosenwasser
et al. 1995; Cookson and Moffatt 2000; Walley et al.
2001). Interleukin 12B (IL12B [MIM 161561]) is lo-
cated in this genomic region and encodes the 40-kDa
subunit of the heterodimeric glycoprotein that is IL12
(Huang et al. 2000). IL12 is an immunomodulatory cy-
tokine that is the primary inducer of the development
of T-helper 1 (Th1) cells, with downregulation of T-
helper 2 (Th2) cytokines that are associated with asthma
(Trinchieri and Scott 1994). IL12 also plays a major role
in the mammalian innate immune response to viruses,
a major trigger for asthma induction (Yap et al. 2000).
Therefore, IL12B is a strong biological candidate gene
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for asthma. Shikano et al. (2001) reported possible ab-
normalities in the IL12 signaling pathways in atopic pa-
tients; however, Noguchi et al. (2001) did not ﬁnd any
association between polymorphisms in IL12B and atopy
phenotypes. Morahan and colleagues (2002) reported an
association between heterozygosity for an IL12B-pro-
moter polymorphism and asthma severity in atopic and
nonatopic individuals. Our objective was to investigate
associations between polymorphisms in IL12B and mild-
to-moderate asthma by use of a family-based approach,
with conﬁrmation by use of a population approach in the
same family sample and in an independent adult sample.
The characteristics of both the pediatric and adult
populations are shown in table 1. The Childhood Asthma
Management Program (CAMP) was a multicenter, ran-
domized, double-masked, placebo-controlled clinical
trial that evaluated the long-term effects of inhaled anti-
inﬂammatory medications in childrenwithmild-to-mod-
erate asthma (Childhood AsthmaManagement Program
Research Group 1999). The diagnosis of asthma was
based on one or more of the following criteria for at
least 6 mo in the year prior to recruitment: (1) asthma
symptoms at least two times per wk, (2) at least two
usages per wk of an inhaled bronchodilator, and (3) daily
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Table 1
Characteristics of Study Population
CHARACTERISTIC
CAMP
ASTHMATIC
CHILDREN
ADULTS
Asthmatics Controls
Population size Np 708 Np 177 Np 177
% male 59.4% 45 62
Age in years (SD) 8.07 (2.1) 33.7 (13.7) 25.7 (7.6)
Ethnicity (%):
Non-Hispanic white 73.4 100 100
African American 9.7 0 0
Hispanic 7.5 0 0
Other 9.2 0 0
Baseline FEV1% predicted (SD) 95.1 (13) 61.8 (10.5) 101.2 (14.6)
asthma medication. Methacholine hyperreactivity, as in-
dicated by the dose of the drug that caused a 20% de-
crease in forced expiratory volume at 1 s (FEV1) was
12.5 mg/ml. Spirometry was performed according to
the American Thoracic Society recommendations, by use
of a volume-displacement spirometer, and airway re-
sponsiveness was assessed by methacholine challenge, by
use of the Wright nebulizer tidal-breathing technique,
during a baseline pretrial period in which children had
been medication-free for at least 28 d (ChildhoodAsthma
Management Program Research Group 1999). Serum eo-
sinophil counts were performed at each enrolling center.
Total serum immunoglobulin E (IgE) was measured us-
ing radioimmunoabsorbent assays from blood samples
collected during the screening sessions.
DNA samples were obtained from 968 children (of
1,041 children who participated in the original CAMP
study) (The Childhood Asthma Management Program
Research Group 2000) and from 1,518 of their parents.
Complete family trios were available for 652 nuclear
families, which included 708 children. Some families had
multiple children with asthma (49 families had two chil-
dren, and 2 families had three children). The character-
istics of these families are shown in table 1.
The adult asthmatics and controls were all white. The
adult cases included 177 patients with asthma who were
originally recruited for an asthma-medication trial in the
United States. To qualify for inclusion, patients had to be
nonsmokers aged 18–45 years, have no signiﬁcant comor-
bid medical conditions, and have diagnostic ﬁndings con-
sistent with moderate-to-severe asthma, according to the
American Thoracic Society criteria (American Thoracic
Society 1987). Patients had an FEV1 of 40%–85% of
the predicted normal values (Crapo et al. 1982) after at
least 8 h of not inhaling beta agonist medications and
after receiving no corticosteroids for at least 6 wk. A
15% change in FEV1 after beta-agonist or methacho-
line-sensitivity testing was used to conﬁrm asthma diag-
nosis. The adult control population included DNA from
177 subjects without asthma from the Environmental
Medicine Genome Bank (Sonna et al. 2000). This DNA
bank consists of DNA collected from U.S. Army recruits
from across the country during basic training: Army re-
cruits are screened to exclude those who have a history
of asthma or obstructive airway disease. The character-
istics of the cases and controls are shown in table 1.
Because 73.4% of the sample was white, SNPs were
chosen to ensure full representation of the gene, on the
basis of haplotypes inferred using the PHASE software
(Stephens et al. 2001), from resequencing data reported
on the University of Washington–Fred Hutchinson Can-
cer Research Center (UW-FHCRC)Web site (accessedDe-
cember 2002). These data were derived from 23 white
individuals who were CEPH parents (DNA from the
Coriell Cell Repository). Haplotypes were inferred using
21 SNPs, for which the minor allele was at a frequency
of 5%. The six common haplotypes in whites, found
at frequencies of 5%, could be distinguished using six
haplotype-tagging SNPs (htSNPs) chosen from the
UW-FHCRC Web site. As a secondary test, we used the
PHASE package (Stephens et al. 2001) to infer haplo-
types from the genotype data in the parents and children
in the CAMP sample and, for conﬁrmation, compared
them with the common haplotypes seen in whites from
the SeattleSNPs CEPH data. In addition to the above
SNPs, we also genotyped the previously reported inser-
tion-deletion SNP in the promoter (Morahan et al. 2002)
in both the CAMP and the adult case-control studies.
Figure 1 shows the location of the 6 htSNPs and the
pairwise linkage disequilibrium with all other SNPs seen
at 5% frequency in the European CEPH sample.
The majority of the SNP genotyping in the CAMP co-
hort and in the case-control cohort was performed using
the Sequenom mass spectrometry genotyping platform
(Sequenom). Multiplex PCR and minisequencing assays
were designed using SpectroDESIGNER software (Seque-
nom). Primers were purchased from Sequenom. Three–
ﬁve-plex PCR reactions were performed using 5 ng of
genomic DNA in 5 ml solution. Protocol details and
primer data are available on the Innate Immunity in
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Figure 1 Pairwise linkage disequilibrium ( ) for IL12B SNPs seen at5% frequency in Europeans in CEPH sample (data fromSeattleSNPs,2r
NHLBI Program for Genomic Applications [UW-FHCRC]). SNP numbering is relative to the gene transcription start codon, with mapping to
the SNPs we tested, using the SeattleSNPs numbering system.
Heart, Lung and Blood Disease page of the Programs
for Genomic Applications Web site. Secondary modiﬁed
single-primer minisequencing reactions were formed in
multiplex and were analyzed using the Bruker Bi-ﬂex
MALDI-TOF mass spectrometer (Bruker Daltonics).
Spectral output was analyzed using SpectroTYPER-RT
software (Sequenom). As a quality control measure, ge-
notyping was repeated for at least 8% of the sample for
each SNP and was tested for discordance.
We resequenced the promoter insertion-deletion SNP
(Morahan et al. 2002) and identiﬁed the following two
alleles: tctaa /. We identiﬁed a 1-bp insertion that arose
whenever there was a deletion; this was in 100% linkage
disequilibrium with the insertion-deletion SNP. We used
the ABI 3100 Sequence Detector (Applied Biosystems)
to identify this base-pair change in both the CAMP and
the adult populations.
The PedCheck program (O’Connell and Weeks 1998)
was used to assess the genotype data for pedigree incon-
sistencies in the CAMP cohort. The genotypes of families
with pedigree errors were set to 0. Hardy-Weinberg equi-
librium was tested in the parental data for each locus,
by use of the x2 goodness-of-ﬁt test.
For the CAMP cohort, the primary analysis was for
association of individual SNPs with the binary trait of
asthma, by use of the family-based association test (FBAT)
program (Horvath et al. 2001), and for haplotypes, by
use of the haplotype extension (HBAT) of the FBAT
program (Horvath et al. 2004). In the FBAT program,
the additive and recessive models were used. Because
SNPs 4237 and 6402 were genotyped ﬁrst and 2 SNP
haplotypes were evaluated, we also report the 4237_6402
haplotype results.
In the CAMP cohort, we performed a second analysis,
to test each individual SNP, with asthma-severity pheno-
types (post-bronchodilator FEV1% predicted and base-
line FEV1) and with atopy phenotypes (logarithm of total
eosinophil number [LOGEOS] and logarithm of total
IgE level [LOGIGE]), using PBAT (the phenotype option
of FBAT) (Lange et al. 2003c). We adjusted for the fol-
lowing covariates, using PBAT (Lange et al. 2004), be-
cause they were statistically signiﬁcant in a regression
model that described the phenotypes as a function of
the covariates age, age at onset, height, weight, and sex.
The genetic model was selected on the basis of condi-
tional power calculations (Lange et al. 2003a). By use
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Figure 2 Box plots of post-bronchodilator FEV1% predicted in the pediatric cohort with mild-to-moderate asthma and of baseline FEV1%
predicted in the adult cases with moderate-to-severe asthma, for SNPs IL12B_4237 and IL12B_6402.
of the Bonferroni correction, the signiﬁcance level of the
FBAT statistic was adjusted for the number of FBATs
computed. Signiﬁcant phenotypes were also tested for
association with the SNP, by use of the population-based
GEE-Wald test for family studies, as suggested by Lange
et al. (2003b). The advantage of this population-based
association test is that data from family-based studies
can be analyzed without use of the genetic information
that is included in the computation for the FBAT statistic
and can therefore be considered as a replication of a
signiﬁcant ﬁnding in the same data set.
For the adult data set, we used linear-regression mod-
eling for each phenotype, as a function of the marker
score and other covariates. The estimates for the genetic
effects and their SEs were used to construct standard
Wald tests, to test for association between the SNPs and
the phenotypes. By use of the technique of Pritchard and
Rosenberg (1999), 49 unlinked SNPs were tested to en-
sure that there was no population stratiﬁcation between
cases and controls.
The recessive model had the most power of all three
models (recessive, dominant, and additive), as evidenced
by conditional power calculations and by visual inspec-
tion of the box plots (ﬁg. 2). Therefore, we show the
results using the recessive model for all analyses.
Hardy-Weinberg equilibrium was conﬁrmed for all loci
in the parents (all P values 1.1). For the family-based
analysis, we analyzed African Americans and whites sep-
arately. Table 2 shows the results for the recessive model
for both ethnicities. The FBAT statistic is highly signiﬁ-
cant for the IL12B_4237 A allele ( ) in whites,Pp .00084
with 269 informative families. Although the FBAT sta-
tistic is signiﬁcant for the G allele in African Americans
( ), African Americans made up only 9.7% ofPp .0031
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Table 2
Family-Based Association Test of IL12B SNPs
in the CAMP Cohort, Using the Recessive Model
MARKER
AND ALLELE
NO. OF INFORMATIVE FAMILIES (P)
White African American
IL12B_4237:
A 54 (.00084) 2 (.41421)
G 215 (.38453) 17 (.0031)
IL12B_13478:
C 37 (.02304) 3 (.7388)
A 183 (.44288) 12 (.4428)
IL12B_2508:
A 127 (.9619) 10 (.3173)
T 262 (.6802) 20 (.0495)
our total cohort, and only 19 families were informative
in this analysis. The IL12B_4237_6402 haplotype analy-
sis was also signiﬁcant for whites (global x2 test for hap-
lotypes 18.8; ), and the 4237A_6402C hap-Pp .0003
lotype was signiﬁcantly undertransmitted to asthmatic
children. In addition, the analysis of all haplotypes for
affection status was also signiﬁcant in whites (global x2
test for haplotypes 13.49; ). By use of the re-Pp .009
cessive model, the family-based association test was also
positive in whites for LOGEOS for SNP IL12B_1025
( ) and for LOGIGE for SNP IL12B_4237Pp .003
( ), with conﬁrmation by use of the population-Pp .002
based method ( and , respectively, withPp .017 Pp .05
estimated heritabilities of 0.02 and 0.13). Because of
the small number of informative families, we did not
repeat the haplotype or phenotype analysis for African
Americans.
In the adult asthmatic cases and nonasthmatic con-
trols, the relative risk of asthma in cases versus controls
with the IL12B_4237 SNP in a homozygous recessive
model was not signiﬁcant ( ; 1 df;2x p 0.1325 Pp
). However, the frequency of the homozygous re-.7158
cessives in the nonasthmatic population was only 5.7%,
and the power to detect a 50% decrease in this frequency
in asthmatics was only 25%. Table 3 lists the P values
for all SNPs genotyped, by use of the baseline FEV1%-
predicted asthma phenotype rather than the affection
status, in the adult cohort, as well as the estimated her-
itabilities in the cohort and the FBAT statistic (recessive
model) for the same SNP in CAMP, when available. The
SNPs IL12B_4237 and _6402 are signiﬁcantly associated
with the baseline FEV1% predicted in the adult cohort.
For SNPs IL12B_4237 and _6402, the associations with
baseline FEV1% predicted in the adult cohort are con-
ﬁrmed in the CAMP study, with post-bronchodilator
FEV1% predicted. Further, ﬁgure 2 shows the box plots
for IL12B_4237 and _6402 in both studies. It is im-
portant to note that, for the two SNPs, the directions
of the effect are the same in both studies.
We subsequently tested the promoter insertion-dele-
tion variant reported elsewhere by Morahan and col-
leagues (2002) to be associated with asthma severity.
This SNP had values for linkage disequilibrium of2r
0.4 with the other six IL12B SNPs tested. We found
no positive associations between this SNP and asthma
or with any of the asthma phenotypes in either the
CAMP population or the adult case-control population,
using recessive, dominant, or additive models.
Our results provide strong suggestive evidence that
polymorphisms in the IL12B gene are associated with
asthma and asthma-related phenotypes in whites. We
found, using a recessive model, that the A allele of the
4237 polymorphism was signiﬁcantly undertransmitted
in white asthmatic probands. In addition, the global test
for IL12B haplotypes across the six SNPs was also sig-
niﬁcantly associated with asthma. We found that, in the
recessive model, atopy phenotypes were associated in
whites with SNPs in IL12B.We conﬁrmed an association
of IL12B with asthma severity in the CAMP cohort, in
an independent adult case-control cohort, using avail-
able phenotypes (post-bronchodilator FEV1% predicted
in CAMP and pre-bronchodilator FEV1% predicted in
the adult population) and a recessive model. We did not
ﬁnd, using any model, any association of the promoter
insertion-deletion SNP—reported elsewhere to be asso-
ciated with asthma severity (Morahan et al. 2002)—with
asthma or asthma-related phenotypes in either the CAMP
or adult cohorts.
The strength of our analyses lies (1) in the replication
of our ﬁndings by use of two different statisticalmethods
(family based and population based) in the CAMP co-
hort and (2) in the replication of the asthma-severity
ﬁnding in the CAMP cohort of mild-to-moderate asth-
matics in an independent adult cohort of moderate-to-
severe asthmatics. Our P values also reﬂect statistical
controls for multiple comparisons. As a quality-control
measure, we also repeated the genotyping for 50% of
the CAMP sample for the two SNPs (IL12B_4237 and
_6402) that were found to be associated with asthma
severity. Our quality-control procedures and the use of
multiple replication methods make it unlikely that geno-
typing error inﬂuenced our results. In addition, IL12B
is a highly plausible candidate gene for asthma. It is in
a location (5q31-33) previously linked repeatedly to
asthma; it is associated with the development of Th1
cells, with downregulation of the release of Th2 cyto-
kines; and it plays a major role in the mammalian innate
immune response to viruses.
The limitations of our study include the fact that the
two study populations used were very different. Onewas
a cohort of children with mild-to-moderate asthma, and
the other was an adult population with moderate-to-
severe asthma. In the adult population, asthma-pheno-
typic information was limited to baseline (prebroncho-
dilator) FEV1% predicted, and we did not replicate the
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Table 3
Population-Based Analysis for Association of IL12B SNPs with Asthma Severity
MARKER
ESTIMATED
HERITABILITYa
(%)
P VALUE FOR GENOTYPED SNPS IN
Adult Cohort CAMP Whitesb CAMP African Americansb
IL12B_4237 3.16 .019 .075 .039
IL12B_6402 3.40 .014 .016 .098
NOTE.—Population-based analysis for association of IL12B SNPs with asthma severity, by use
of the recessive model (baseline FEV1%) predicted in the adult cohort and post-bronchodilator
FEV1% predicted in the CAMP cohort.
a Estimated heritability is for the adult cohort and is the percentage of explained phenotypic
variance.
b By use of FBAT.
exact phenotype found to be strongly associated with
asthma in the adult population. This is most likely be-
cause baseline FEV1% predicted in the children with
mild-to-moderate asthma was 95.1%, which is close to
that of normal controls (see table 1). Other study lim-
itations include the fact that all results were reported in
the recessive model, since that was the model shown to
have the most power. Because we did not measure IL12B
levels, we could not correlate the genotype results with
IL12B production. In addition, the case-control popu-
lation was relatively small, which did not allow us to
conﬁrm the association of the IL12B_4237 SNP with the
asthma phenotype in whites.
We failed to replicate the ﬁndings of Morahan and
colleagues (2002) that heterozygosity for an insertion-
deletion polymorphism in the IL12B promoter was as-
sociated with asthma severity. In fact, we found no as-
sociation between this variant and asthma or asthma
phenotypes in any population or statistical model. Khoo
and colleagues (2004) also failed to ﬁnd an association
between asthma severity and this polymorphism in a
population of asthmatic subjects for whom comprehen-
sive data on asthma severity was followed from birth to
age 42 years. This polymorphism was recently shown
to be functional, with homozygotes for one allele show-
ing a marked difference in secretion of IL12B (Muller-
Berghaus et al. 2004). Although this SNP appears to be
functional, our ﬁndings are consistent with those of Khoo
et al. (2004), which show no association between this
SNP and asthma severity.
The SNP that we found to be most positively asso-
ciated with asthma was the IL12B_4237 SNP. This is an
intronic SNP, and, using Neural Network Splice version
0.9 located on the Berkeley Drosophila Genome Project
Web site, we found no evidence that this was a splice
site. This SNP is in almost complete linkage disequilib-
rium with SNP IL12B_14962 (see ﬁg. 1, where 2542p
4237 and 13168p14962), an SNP in the 3′ UTR. In
addition, chromosome 5q31 contains numerous immu-
noregulatory genes that have been linked to asthma in
various studies (Meyers et al. 1994; Rosenwasser et al.
1995; Cookson and Moffatt 2000; Walley et al. 2001),
and it is possible that the associations we found in IL12B
are the result of linkage disequilibrium with other im-
portant SNPs in other genes.
In conclusion, we present data that suggest that mul-
tiple SNPs in IL12B are associated with asthma pheno-
types in whites. Our strongest ﬁnding was for asthma-
severity phenotypes. The biologic importance of these
SNPs is currently unclear, and further functional testing
of these SNPs—and other SNPs that are in high linkage
disequilibrium with them—is required.
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